Treats schizophrenia. ANDA 90695, held by Lannett Co Inc. Loxapine Succinate.
As of Nov 16, 2026, ANDA 90695 (Loxapine Succinate), held by Lannett Co Inc, was first approved by FDA on Sep 26, 2011, with 2 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Loxapine Capsules, USP are indicated for the treatment of schizophrenia. The efficacy of loxapine in schizophrenia was established in clinical studies which enrolled newly hospitalized and chronically hospitalized acutely ill schizophrenic patients as subjects.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 26, 2011 | Original application | Approved | None posted |
| Loxapine SuccinateEQ 5MG BASE · capsule;oral | Loxapine Succinate | Rx |
| Loxapine SuccinateEQ 10MG BASE · capsule;oral | Loxapine Succinate | Rx |
| Loxapine SuccinateEQ 25MG BASE · capsule;oral | Loxapine Succinate | Rx |
| Loxapine SuccinateEQ 50MG BASE · capsule;oral | Loxapine Succinate | Rx |
| Jan 22, 2025 | Supplement 19Labeling · Standard review | Approved | None posted |
| Feb 23, 2017 | Supplement 5Labeling · Standard review | Approved | None posted |
| Sep 26, 2011 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters